Last reviewed · How we verify
Nevirapine (Viramune)
Nevirapine inhibits HIV reverse transcriptase, blocking the enzyme that converts viral RNA into DNA and preventing HIV replication.
Nevirapine inhibits HIV reverse transcriptase, blocking the enzyme that converts viral RNA into DNA and preventing HIV replication. Used for HIV-1 infection (in combination with other antiretroviral agents), Prevention of mother-to-child transmission of HIV.
At a glance
| Generic name | Nevirapine (Viramune) |
|---|---|
| Sponsor | Germans Trias i Pujol Hospital |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV reverse transcriptase and blocks its catalytic activity. By preventing the conversion of viral RNA to DNA, it interrupts the HIV replication cycle early in infection. It is used as part of combination antiretroviral therapy to suppress viral load in HIV-infected patients.
Approved indications
- HIV-1 infection (in combination with other antiretroviral agents)
- Prevention of mother-to-child transmission of HIV
Common side effects
- Rash
- Stevens-Johnson syndrome
- Hepatotoxicity
- Nausea
- Headache
- Fever
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (PHASE1, PHASE2)
- Population Pharmacokinetics of Antiretroviral in Children
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nevirapine (Viramune) CI brief — competitive landscape report
- Nevirapine (Viramune) updates RSS · CI watch RSS
- Germans Trias i Pujol Hospital portfolio CI